menu search

KROS / Keros Therapeutics: Market Rewarding KER-050 Trial Momentum

Keros Therapeutics: Market Rewarding KER-050 Trial Momentum
Data is promising for KROS' KER-050 compound; investors are rewarding the company on its novel hypotheses. We performed a deep dive on its most recent readouts on KER-050. Read More
Posted: Feb 10 2023, 23:36
Author Name: Seeking Alpha
Views: 110530

KROS News  

Keros Therapeutics, Inc. (KROS) Upgraded to Buy: Here's What You Should Know

By Zacks Investment Research
May 1, 2023

Keros Therapeutics, Inc. (KROS) Upgraded to Buy: Here's What You Should Know

Keros Therapeutics, Inc. (KROS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This m more_horizontal

Keros Therapeutics: Undercovered Company With Data From All Programs

By Seeking Alpha
April 30, 2023

Keros Therapeutics: Undercovered Company With Data From All Programs

KROS is a small company with three clinical programs. Surprisingly, each program has clinical data. more_horizontal

Why Shares of Keros Therapeutics Jumped This Week

By The Motley Fool
April 21, 2023

Why Shares of Keros Therapeutics Jumped This Week

Keros is a pre-revenue biotech with two therapies in phase 2 trials. The company focuses on treatments for blood and musculoskeletal disorders. more_horizontal

Is a Surprise Coming for Keros Therapeutics (KROS) This Earnings Season?

By Zacks Investment Research
March 2, 2023

Is a Surprise Coming for Keros Therapeutics (KROS) This Earnings Season?

Keros Therapeutics (KROS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal

Keros Therapeutics: Market Rewarding KER-050 Trial Momentum

By Seeking Alpha
February 10, 2023

Keros Therapeutics: Market Rewarding KER-050 Trial Momentum

Data is promising for KROS' KER-050 compound; investors are rewarding the company on its novel hypotheses. We performed a deep dive on its most recent more_horizontal

Keros Therapeutics, Inc. (KROS) Upgraded to Buy: Here's What You Should Know

By Zacks Investment Research
December 23, 2022

Keros Therapeutics, Inc. (KROS) Upgraded to Buy: Here's What You Should Know

Keros Therapeutics, Inc. (KROS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank more_horizontal

Keros Therapeutics, Inc. (KROS) Upgraded to Buy: Here's What You Should Know

By Zacks Investment Research
November 8, 2022

Keros Therapeutics, Inc. (KROS) Upgraded to Buy: Here's What You Should Know

Keros Therapeutics, Inc. (KROS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This m more_horizontal


Search within

Pages Search Results: